Leeds Teaching Hospitals NHS Trust (LTHT) has launched a city-wide multidisciplinary COVID-19 Vaccine Trial Delivery Team to plan for large scale recruitment across Leeds, Harrogate and York.
Together with partners Leeds Community Health NHS Trust, Leeds CCG, Leeds and York Partnership Trust, Harrogate and District NHS Foundation Trust and the Yorkshire & Humber National Institute of Health Research (NIHR) Clinical Research Network (CRN), the delivery team will put together the resources and infrastructure required to recruit up to 250 participants a day.
Julian Hartley, Chief Executive of Leeds Teaching Hospitals NHS Trust said: “An effective vaccine against the coronavirus is a key strategy to end the devastating impact the virus has had on the world.
“We are working extremely hard to put together plans not only to trial vaccines in Leeds but to work alongside our partners in Harrogate and York to make sure our whole community is involved and that we have an accessible vaccine process for all.”
“To register interest in taking part in a COVID-19 vaccine study please visit the NHS COVID-19 vaccine research registry website.”
Professor Alistair Hall Alistair Hall, Clinical Director of the NIHR Clinical Research Network (CRN) Yorkshire and Humber said: “The whole community of Yorkshire have shared a common purpose throughout the COVID-19 pandemic and as we look to come out at the other side we need as many people as possible to take part in vaccine studies so we can beat this virus together.
“There are a number of different studies being considered for the region at the moment so more details on each vaccine will be released in the coming weeks.
“For now we need people to register their interest in taking part so when we are ready to start recruiting participants we can get in contact right away.”
COVID-19 vaccine research ‘Frequently Asked Questions’ published
Even though COVID-19 vaccines have started to be distributed across the country, COVID-19 vaccine research still needs to continue to find more effective vaccines and some vaccines may be more suitable for different groups of people. The FAQs also answer questions about how COVID-19 vaccines have been developed and participating in health research more generally.
If you would like to discuss the FAQs, please contact Amy Rebane on email@example.com